NOEMX
Price
$11.17
Change
-$0.02 (-0.18%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

NOEMX vs RNWFX

Header iconNOEMX vs RNWFX Comparison
Open Charts NOEMX vs RNWFXBanner chart's image
Northern Emerging Markets Equity Index
Price$11.17
Change-$0.02 (-0.18%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
NOEMX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
NOEMX vs. RNWFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NOEMX is a Hold and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. NOEMX (1.77B). NOEMX pays higher dividends than RNWFX: NOEMX (3.78) vs RNWFX (1.51). NOEMX was incepted earlier than RNWFX: NOEMX (19 years) vs RNWFX (23 years). NOEMX is a more actively managed with annual turnover of: 57.68 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than NOEMX: RNWFX (250) vs NOEMX (2500). NOEMX annual gain was more profitable for investors over the last year : 9.74 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. NOEMX (6.73).
NOEMXRNWFXNOEMX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence19 years23 years-
Gain YTD7.3884.549162%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRA500N/A-
Net Assets1.77B62.2B3%
Annual Yield % from dividends3.781.51251%
Returns for 1 year9.745.86166%
Returns for 3 years-5.22-5.10102%
Returns for 5 years6.7314.3947%
Returns for 10 years35.1242.6782%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics